AB	antibody
Akt	protein kinase B
AML	acute myeloid leukemia
APC	antigen presenting cell
AUC	area under curve
β2m	beta-2 microglobulin
B-ALL	B cell acute lymphoblastic leukemia
BCMA	B cell maturation antigen
BCR	B cell receptor
BTK	Bruton’s tyrosine kinase
CAIX	carbonic anhydrase IX
CAR	chimeric antigen receptor
CD	cluster of differentiation
CDK4/6	cyclin dependent kinase 4 and 6
CLL	chronic lymphocytic leukemia
CR	complete remission
CRC	colorectal cancer
CRS	cytokine release syndrome
CT	computed tomography
CTLA-4	cytotoxic T-lymphocyte protein 4
CTx	chemotherapy
DLBCL	diffuse large B cell lymphoma
DLT	dose limiting toxicity
dMMR	mismatch repair deficiency
EGFR	epidermal growth factor receptor
EGFRvIII	epidermal growth factor receptor variant III
ERK	extracellular signal-regulated kinase
FDA	Food and Drug Administration
GD2	disialoganglioside
GVHD	graft-versus-host disease
GSK-3	serine/threonine kinase glycogen synthase kinase 3
HCC	hepatocellular carcinoma
HER2	human epidermal growth factor receptor 2
HL	Hodgkin’s lymphoma
HLA	human leukocyte antigen
HNSCC	head and neck squamous cell carcinoma
HR	hazard ratio
ICI	immune-checkpoint inhibitors
IHC	immunohistochemistry
IL	interleukin
IFNγ	interferon-gamma
IRAE	immune-related adverse events
ITK	interleukin-2 inducible T cell kinase
ITIM	immunoreceptor tyrosine-based inhibitory motif
ITSM	immunoreceptor tyrosine-based switch motif
JAK	Janus kinase
LAG-3	lymphocyte-activation gene 3
LAT	linker for activation of T cells
Lck	lymphocyte-specific protein tyrosine kinase
LOH	loss of heterozygosity
LOHHLA	Loss of Heterozygosity in Human Leukocyte Antigen
MAPK	mitogen-activated protein kinase
MCL	mantle cell lymphoma
MHC	major histocompatibility complex
MRT	magnetic resonance tomography
MSI-H	microsatellite instability
mTOR	mechanistic target of rapamycin
MUC1	mucin 1
NFAT	nuclear factor of activated T cells
NK cell	natural killer cell
NKT cell	natural killer T cell
NFKB	nuclear factor kappa-light-chain-enhancer of activated B cells
NHL	non-Hodgkin lymphoma
NR2F6	nuclear receptor subfamily 2 group F member 6
NSCLC	non-small cell lung cancer
OS	overall survival
ORR	overall response rate
PD-1	programmed cell death protein 1
PD-L1	programmed cell death-ligand 1
PET	positron emission tomography
PFS	progression-free survival
PI3K	phosphatidylinositol 3-kinase
PKC	protein kinase C
PLCg	phospholipase C gamma 1
PMBCL	primary mediastinal B cell lymphoma
PR	partial remission
RCC	renal cell carcinoma
RGMb	repulsive guidance molecule B
SBRT	stereotactic body radiotherapy
scFV	single-chain variable fragment
SCNA	somatic copy number alterations
SHP	small heterodimer partner
shRNA	small hairpin RNA
SPECT	single photon emission computed tomography
SUV	standardized uptake value
TAP	transporter associated with antigen processing
tbx21	T-box transcription factor 21
TCGA	The Cancer Genome Atlas
TCR	T cell receptor
TFH	T follicular helper cell
TFR	T follicular regulatory cell
TH2	T helper 2 cell
TILs	tumor infiltrating lymphocytes
TIM-3	T cell membrane protein 3
TKI	tyrosine kinase inhibitor
TMB	tumor mutational burden
TNBC	triple negative breast cancer
TNFα	tumor necrosis factor alpha
TOX	thymocyte selection-associated high mobility group box protein TOX
TPS	tumor proportion score
Treg	regulatory T cell
Tx	therapy
VEGF	vascular endothelial growth factor
VEGFR	vascular endothelial growth factor receptor
ZAP70	zeta chain-associated protein kinase 70